Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*

The CARTIHEAL Implant will be featured at the Arthroscopy Association of North America Annual Meeting (AANA 2025) this week

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces encouraging results for its CARTIHEAL AGILI-C Cartilage Repair Implant from a recent multicentre randomised controlled trial (RCT) treating knee cartilage defects. When compared to the current surgical standard of care,* the implant demonstrated: 

  • Superior pain relief: Patients treated with the CARTIHEAL AGILI-C Implant reported significantly better knee pain relief, and quality of life improvements over a 4-year period.1-3 ** 
  • Superior functional gains: Patients treated with the CARTIHEAL Implant reported superior improvements in performing activities related to daily living, sport and recreation at 2 and 4 years. 1-3
  • Different patient profiles – same great results: The scaffold effectively treated a broad group of patients across age, lesion size, and presence of osteoarthritis while delivering clinically meaningful results.1-3 ** 


[img]http://phpstack-1214942-4313335.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=629d76d6-a68d-4234-950a-f631deda7ac0&size=0[/img]

Smith+Nephew's FDA-approved CARTIHEAL Implant, which previously received breakthrough designation, is revolutionizing the cartilage repair landscape. In line with AANA's mission to improve patient outcomes through education and innovation, the implant’s broad indication allows physicians to treat patients who previously may not have had access.

Professor Elizaveta Kon from Humanitas Research Hospital, who plans to present 4-year outcomes of the implant with respect to gender during AANA 2025, highlighted the importance of inclusivity in study design. “We need a technology that we can trust to work in the patients we see day-to-day. This is where CARTIHEAL has excelled, showcasing superior performance across genders, lesion location, and more.”

Dr. Vinod Dasa of Louisiana State University School of Medicine finds the technology particularly meaningful for his patients. 'The patients that come to see me are looking for a bridging procedure that enables them to continue their day-to-day life, playing with their kids and grandkids. In addition to the pain relief and functional gains, the 87% reduction in the risk of subsequent total knee arthroplasty (TKA) and osteotomy compared to the surgical standard of care resonates with almost every patient. The potential to delay if not avoid TKA is top of mind of almost every patient with mild/moderate osteoarthritis.'

Using the CARTIHEAL Implant to treat a spectrum of cartilage pathologies will be featured during a lunch symposium on Friday, May 9 during AANA 2025. You can also learn more by visiting the CARTIHEAL Implant webpage here. 

To learn more about Smith+Nephew’s Sports Medicine joint repair solutions and enabling technologies, please visit our booth (#303) at AANA 2025 in Washington DC May 8-10, or visit www.smith-nephew.com. 


- ends –


Media Enquiries 

Dave Snyder          +1 (978) 749-1440 

Smith+Nephew      david.snyder@smith-nephew.com


* compared to debridement or microfracture  
  
**  over a 2- and 4-year follow-up  

 

References

Conte P, Anzillotti G, Crawford DC, et al. Differential analysis of the impact of lesions' location on clinical and radiological outcomes after the implantation of a novel aragonite-based scaffold to treat knee cartilage defects. Int Orthop. 2024;48(12):3117-3126  Altschuler N, Zaslav KR, Di Matteo B, et al. Aragonite-Based Scaffold Versus Microfracture and Debridement for the Treatment of Knee Chondral and Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial. Am J Sports Med. 2023;51(4):957-967  Kon, E., De Caro, F., Dasa, V., M Scopp, J., Di Matteo, B., Flanigan, D., Shabshin, N., Strickland, S., & Altschuler, N. (2025). Female patients report comparable results to males after the implantation of an aragonite-based scaffold for the treatment of knee chondral and osteochondral defects: a gender-based analysis of a RCT at 4 years' follow-up. J of Ortho and Traumatology, 26(1), 17. https://doi.org/10.1186/s10195-025-00829-y

 

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.


Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

 

Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.


Study shows patients treated with Smith+Nephew’s CARTIHEAL™ AGILI-C™ Cartilage Repair Implant have an 87% lower relative risk of Total Knee Arthroplasty or Osteotomy at 4 years¹*


TIN LIÊN QUAN

Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025

[img]http://phpstack-1214942-4313335.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=c8d2ae36-3ba6-4cad-9671-c215c3127cfe&size=0[/img]Globenewswire -

Smith+Nephew introduces CORIOGRAPH™ Pre-Op Planning and Modeling Services for Total Hip Arthroplasty

[img]http://phpstack-1214942-4313335.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=f8f1b172-ac2a-4fa8-a80d-03ab44cdd1c8&size=0[/img]Globenewswire -

Smith+Nephew takes centre court sponsoring players competing at Wimbledon; global Sports Medicine technology leader helping athletes get back in the game

[img]http://phpstack-1214942-4313335.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=7f8ed9d8-7672-4ea8-ad64-2dbd4b3afa9b&size=0[/img]

New report confirms Smith+Nephew’s OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty

[img]http://phpstack-1214942-4313335.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=c0acdffd-9f77-4227-90a5-f22cf9ce03e8&size=0[/img]Globenewswire -

Smith+Nephew expands AETOS™ Shoulder System with new stemless option for anatomic shoulder arthroplasty

[img]http://phpstack-1214942-4313335.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=9fa5e304-173d-4d83-8db1-449505a5b0d6&size=0[/img]Globenewswire -

THỦ THUẬT HAY

Mua laptop Alien hay build PC để dựng video + After Effect?

Qua tìm hiểu thì cũng ngắm được vài em Alien trong tầm chi trả, nhưng cũng có vài anh em chia sẻ là nên dựng PC ở nhà.

Hướng dẫn cách thu nhỏ giao diện của Task Manager

Task Manager là một tính năng quan trọng cho người dùng Windows. Với công cụ này, người dùng có thể làm được nhiều công việc khác nhau như kiểm tra các ứng dụng, quá trình (process) và dịch vụ (service) hiện đang chạy

EaseUS Partition Master: Thay đổi kích cỡ hoặc di chuyển phân vùng ổ cứng

EaseUS Partition Master giúp thay đổi kích cỡ / di chuyển phân vùng ổ cứng để tận dụng không gian đĩa đặc biệt là mở rộng hệ thống ổ đĩa (ổ đĩa C) để giải quyết vấn đề dung lượng lưu trữ ổ cứng thấp

Đây là cách ẩn ứng dụng ở màn hình chính iPhone trên iOS 15 bạn nên lưu ngay

Người dùng iPhone trước đây chắc hẳn sẽ có những ứng dụng riêng tư nhưng không thể ẩn chúng đi ở ngoài màn hình chính, nhưng với iOS 15, bạn đã có thể ẩn đi một hoặc nhiều ứng dụng một cách dễ dàng.

Hướng dẫn xem trực tiếp bóng đá Sea Games 29 qua mạng

SEA Games 29 đã chính thức khởi tranh lúc 15h00 chiều ngày 14/8, toàn bộ các trận đấu sẽ tường thuật trực tiếp trên kênh VTV6 và VTV6 HD.

ĐÁNH GIÁ NHANH

Energizer UE20100CQ pin dự phòng không thể thiếu cho những chuyến du lịch

Với những chuyến đi xa hoặc những ai có nhu cầu trang bị theo mình một pin dự phòng “trâu bò” nhưng phải bảo đảm chất lượng thì Energizer UE20100CQ chắc chắn là sự lựa chọn hoàn hảo. Energizer là thương hiệu đến từ Mỹ,

Đánh giá nhanh Vivo Y71: Lựa chọn phù hợp cho người dùng có ít kinh phí

Nhìn vào mặt trước, Vivo Y71 trông không hề khác biệt so với những thiết bị đắt tiền hơn. Nó có viền 2 bên rất mỏng, gần như không tồn tại, trong khi viền ở cạnh trên và dưới cũng được thu hẹp đáng kể, tạo nên vẻ đẹp

Trên tay Jabra 710 - loa chuyên dùng cho thoại hội nghị

Nếu bạn thường xuyên phải họp hội nghị qua điện thoại, hoặc thường xuyên nghe điện thoại bằng loa ngoài (speaker phone) thì loa Jabra 710 này có khả năng đáp ứng được nhu cầu của bạn.